Structure-activity and structure-side-effect relationships for the quinolone antibacterials
about
Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infectionsDegradation of the fluoroquinolone enrofloxacin by the brown rot fungus Gloeophyllum striatum: identification of metabolitesAntimicrobial safety: focus on fluoroquinolonesPrediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screeningAnti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniquesA new approach for early assessment of the epileptogenic potential of quinolonesStructure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 positionN-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studiesAdvances in DNA gyrase inhibitors.Gatifloxacin, an advanced 8-methoxy fluoroquinolone.Selective entrapment of the cationic form of norfloxacin within anionic sodium dodecyl sulfate micelles at physiological pH and its effect on the drug photodecomposition.Comparative study of the antimutagenic properties of vitamins C and E against mutation induced by norfloxacinReal-time visualization of photochemically induced fluorescence of 8-halogenated quinolones: lomefloxacin, clinafloxacin and Bay3118 in live human HaCaT keratinocytes.Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistanceEfficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review.Possible intermolecular interaction between quinolones and biphenylacetic acid inhibits gamma-aminobutyric acid receptor sitesPharmacokinetics of gatifloxacin in infants and childrenEffects of novel 6-desfluoroquinolones and classic quinolones on pentylenetetrazole-induced seizures in mice.Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors.Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactionsClinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.Clinafloxacin pharmacokinetics in subjects with various degrees of renal function.Drug interactions with clinafloxacin.Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent.Clinical use of fluoroquinolones in children.Detection and prevention of ocular phototoxicity of ciprofloxacin and other fluoroquinolone antibioticsClinical pharmacology of gatifloxacin, a new fluoroquinolone.Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations.Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity.Fluoroquinolone adverse effects and drug interactions.Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus.Mirtazapine therapy for dysgeusia in an elderly patient.Grepafloxacin: an overview of antibacterial activity, pharmacokinetics, clinical efficacy and safety.Prulifloxacin: a new antibacterial fluoroquinolone.A review of antibiotics in dermatology.QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor
P2860
Q26746197-8F988211-FFD6-4D0B-8646-8AED0BB00BFBQ28254007-B57730E4-6B73-4B98-A0A4-9FC724C30476Q28255152-82503B95-DB0E-4072-B813-8447F4CE9BBBQ28344748-6A9D05DF-7556-48D0-8FC5-97EF113E02E1Q28344751-5A6369BC-40DC-48D8-8177-E9DAE057E32AQ28369049-FCCB0E77-53FE-46D4-B2B2-F88C49674FA8Q28379263-D97C6A5D-5417-48CB-AAB3-AD2F8AA8805EQ28379303-4CBF8ACE-B543-4E4C-9946-AF770B876996Q31935738-D33ECF87-7254-4EB9-BAB0-1F005FC5122DQ31975922-343E00AF-DA6D-48D3-ABDB-4B95811CEAFDQ33220958-F28CA41A-B96A-4B53-B8FA-8095699D213FQ33319312-9E24F7C1-A87F-41CF-917B-CFD0A0F6646AQ33584190-A0E92730-5101-47D7-8675-C9175079912CQ33614494-072AD3AE-5EF4-4CE5-90B8-8CFBBFD8A20EQ33739099-697D13ED-7E95-4013-81F2-A15D56995F64Q33760893-A51D40C4-671B-435F-B7CA-2CDFCC4B4073Q33856763-80034CB9-3465-494B-BAFA-6E46B623950CQ33866649-67F4E8D5-FA09-46E7-B26E-8F14129DC5D0Q33871466-3CEB2FBE-DC24-4FE6-8A40-22667F7AFB57Q33947205-CB654144-8D32-42C8-B5AE-13BEFA370740Q33980991-6B487000-7A93-40EB-8DB8-B8146F0762FAQ33981431-F20B32C6-A83E-4EA7-BF35-292007970B51Q33982914-86C07378-6FCB-4997-A25A-42E3184595F2Q33982922-8FC4871F-07B4-427D-80A2-BE26C0AE4F63Q33983352-2A74FBF8-2205-4651-9FF0-175260D58719Q33985235-EF3636E9-1BCB-4E78-AFFF-DCA8344E34F4Q34020997-8D281FE0-584A-43DF-B708-02D8890E4DCEQ34030783-ED73FA1E-CBE8-4D92-900E-94BDF61DBEC9Q34104362-3B85BEC9-1270-4424-B02D-DB6A37DAB437Q34142238-CCE3ED13-7DF0-4EAF-A797-91D5A3C48DBFQ34186776-9F959875-8B53-46F2-84C6-0F7877FECA4CQ34347885-C2CEEE68-36D2-4EE2-B04D-6E2E7262A416Q34408447-E8819D57-135D-4697-ACA8-075A494D7FDCQ34528916-A5077871-051D-43DD-91C6-E151704BE4B2Q34557847-51A9A376-4CC6-47EA-86DB-114BED0CF19EQ34558942-1AE18F59-F44B-4B90-9AC4-3D8815CAA333Q34564526-5C4CA1C7-3865-4B27-8734-006C7DA06FA5Q34625911-739158A9-1996-406B-B653-18B5DFEAF9ADQ34634216-7BED252D-71D0-40F9-AC80-8D565269285CQ35003633-AB58B564-0A12-4025-9D40-4FCDB9CCE661
P2860
Structure-activity and structure-side-effect relationships for the quinolone antibacterials
description
1994 nî lūn-bûn
@nan
1994 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Structure-activity and structu ...... r the quinolone antibacterials
@ast
Structure-activity and structu ...... r the quinolone antibacterials
@en
Structure-activity and structu ...... r the quinolone antibacterials
@nl
type
label
Structure-activity and structu ...... r the quinolone antibacterials
@ast
Structure-activity and structu ...... r the quinolone antibacterials
@en
Structure-activity and structu ...... r the quinolone antibacterials
@nl
prefLabel
Structure-activity and structu ...... r the quinolone antibacterials
@ast
Structure-activity and structu ...... r the quinolone antibacterials
@en
Structure-activity and structu ...... r the quinolone antibacterials
@nl
P3181
P356
P1476
Structure-activity and structu ...... r the quinolone antibacterials
@en
P2093
J M Domagala
P304
P3181
P356
10.1093/JAC/33.4.685
P407
P577
1994-04-01T00:00:00Z